CBD offerings by DCs rise more than 5%, according to new 2020 survey

Last year CBD debuted on the Chiropractic Economics Salary & Expense Survey, the chiropractic industry’s standard for financials and product use for doctors of chiropractic (DCs) in the United States.

This year for the 23rd edition of the survey, the number of DCs offering CBD or CBD products rose to 29%.

While the CBD industry awaits a national referendum on CBD use, and states have been left largely to their own devices, last month Virginia became the first state to regulate CBD products as food, ushering-in state regulations on products.

The bill allows the Virginia Department of Agriculture and Consumer Services to regulate and enforce standards for hemp extract, including labeling requirements, identifying contaminants and batch testing.

Hemp plants can not exceed THC levels of 0.3% or they must be destroyed via federal standards, as THC is the intoxicating component in marijuana. CBD does not cause a “high” and is used for a wide variety of treatments, from anxiety to pain relief, according to the World Health Organization.

Last year major pharmacy chains began selling CBD products, but not CBD food products, in states that allowed CBD sales. While it has yet to receive U.S. Food & Drug Administration approval, consumers are flocking to CBD for numerous purported benefits, from treating pain relief, depression and anxiety, to alleviating cancer symptoms and some neurological disorders.

The 2020 Chiropractic Economics Salary & Expense Survey is the go-to source for annual salary data and trending information in the chiropractic industry.

To receive the full 2020 survey results before they are published in late May, click here for a free subscription to Chiropractic Economics.